PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
24492363-2	2014	Isavuconazole was effective, with MIC and minimal fungicidal concentration (MFC) values ranging between 0.125 and 1.00 mug/ml.	isavuconazole	0-13	microphthalmia Japan	Mus musculus	34-37
24100500-0	2013	Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.	isavuconazole	0-13	cytochrome P450, family 51	Mus musculus	146-151
34543091-2	2021	isolates to 5 antifungal drugs (amphotericin B, voriconazole, posaconazole, isavuconazole, terbinafine) by EUCAST method.	isavuconazole	76-89	calpastatin	Homo sapiens	107-113
33008918-0	2020	Domain-Swap Dimerization of Acanthamoeba castellanii CYP51 and a Unique Mechanism of Inactivation by Isavuconazole.	isavuconazole	101-114	cytochrome P450 family 51 subfamily A member 1	Homo sapiens	53-58
33963620-2	2021	Isavuconazole is metabolized by CYP3A4 and CYP3A5 and it has been shown that the CYP3A inducer rifampin reduces isavuconazole exposure.	isavuconazole	0-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
33963620-2	2021	Isavuconazole is metabolized by CYP3A4 and CYP3A5 and it has been shown that the CYP3A inducer rifampin reduces isavuconazole exposure.	isavuconazole	0-13	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	43-49
33963620-2	2021	Isavuconazole is metabolized by CYP3A4 and CYP3A5 and it has been shown that the CYP3A inducer rifampin reduces isavuconazole exposure.	isavuconazole	0-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-37
33963620-5	2021	Moreover, although it is well known that CYP3A enzymes are important for the metabolism of isavuconazole, this induction-effect has never been studied in combination with the patient"s CYP3A genotype.	isavuconazole	91-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-46
33963620-6	2021	PATIENTS: We report three patients treated with both isavuconazole and a CYP3A inducer that is less potent compared to rifampin (rifabutin or phenobarbital), in whom we determined isavuconazole concentrations.	isavuconazole	180-193	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-78
33963620-7	2021	RESULTS: These cases suggest that the CYP3A4/5 genotype is an important determinant for isavuconazole exposure and that it might also influence the CYP450-induction interaction.	isavuconazole	88-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
33963620-8	2021	CONCLUSIONS: CYP3A-inducers that are less potent compared to rifampin, may be combined with isavuconazole in patients with loss of CYP3A5 activity (CYP3A5*3/*3).	isavuconazole	92-105	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	131-137
33963620-8	2021	CONCLUSIONS: CYP3A-inducers that are less potent compared to rifampin, may be combined with isavuconazole in patients with loss of CYP3A5 activity (CYP3A5*3/*3).	isavuconazole	92-105	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	148-154
33963620-10	2021	However, low isavuconazole exposure was observed in the extensive metabolizer with CYP3A4*1/*1 and CYP3A5*1/*3 alleles.	isavuconazole	13-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
33963620-10	2021	However, low isavuconazole exposure was observed in the extensive metabolizer with CYP3A4*1/*1 and CYP3A5*1/*3 alleles.	isavuconazole	13-26	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	99-105
31119272-9	2019	In multivariate analysis the association between the length of treatment and higher levels of isavuconazole (P < 0.001) and higher serum GGT and lower isavuconazole levels (P = 0.001) was confirmed.	isavuconazole	94-107	gamma-glutamyltransferase light chain 5 pseudogene	Homo sapiens	140-143
31877348-0	2020	The antifungal isavuconazole inhibits the entry of lassa virus by targeting the stable signal peptide-GP2 subunit interface of lassa virus glycoprotein.	isavuconazole	15-28	glycoprotein 2	Homo sapiens	102-105
31877348-4	2020	Fragment replacement mutational study indicated that isavuconazole targets the stable signal peptide (SSP)-membrane fusion subunit (GP2) interface of Lassa glycoprotein.	isavuconazole	53-66	glycoprotein 2	Homo sapiens	132-135
31877348-5	2020	Further mutational study of the SSP-GP2 region of LASV glycoprotein revealed that S27 in the N-terminal transmembrane region of SSP and V431, F434 and V435 in the transmembrane domain of GP2 affect anti-LASV activity of isavuconazole.	isavuconazole	220-233	glycoprotein 2	Homo sapiens	36-39
31877348-5	2020	Further mutational study of the SSP-GP2 region of LASV glycoprotein revealed that S27 in the N-terminal transmembrane region of SSP and V431, F434 and V435 in the transmembrane domain of GP2 affect anti-LASV activity of isavuconazole.	isavuconazole	220-233	ribosomal protein S27	Homo sapiens	82-85
31877348-5	2020	Further mutational study of the SSP-GP2 region of LASV glycoprotein revealed that S27 in the N-terminal transmembrane region of SSP and V431, F434 and V435 in the transmembrane domain of GP2 affect anti-LASV activity of isavuconazole.	isavuconazole	220-233	glycoprotein 2	Homo sapiens	187-190
31791946-3	2020	Here, we described a leading compound, NT-a9, an analogue of isavuconazole, that showed strong antifungal activities in vitro and in vivo NT-a9 showed a wide range of activities against several pathogenic fungi in vitro, including Cryptococcus neoformans, Cryptococcus gattii, Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata, and Candida parapsilosis, with MICs ranging from 0.002 to 1 mug/ml.	isavuconazole	61-74	nuclear encoded tRNA alanine 9 (anticodon AGC)	Mus musculus	39-44
31791946-3	2020	Here, we described a leading compound, NT-a9, an analogue of isavuconazole, that showed strong antifungal activities in vitro and in vivo NT-a9 showed a wide range of activities against several pathogenic fungi in vitro, including Cryptococcus neoformans, Cryptococcus gattii, Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata, and Candida parapsilosis, with MICs ranging from 0.002 to 1 mug/ml.	isavuconazole	61-74	nuclear encoded tRNA alanine 9 (anticodon AGC)	Mus musculus	138-143
31791946-9	2020	In the survival study, NT-a9 significantly prolonged the survival times of mice compared with the survival times of the control group or the isavuconazole-, fluconazole-, or amphotericin B-treated groups.	isavuconazole	141-154	nuclear encoded tRNA alanine 9 (anticodon AGC)	Mus musculus	23-28
31310805-0	2019	Isavuconazole and voriconazole inhibition of sterol 14alpha-demethylases (CYP51) from Aspergillus fumigatus and Homo sapiens.	isavuconazole	0-13	sterol 14-demethylase	Saccharomyces cerevisiae S288C	74-79
31310805-1	2019	Here we report the first evaluation of isavuconazole inhibition of Aspergillus fumigatus CYP51 and thus sterol biosynthesis in the fungus.	isavuconazole	39-52	sterol 14-demethylase	Saccharomyces cerevisiae S288C	89-94
31310805-2	2019	Voriconazole and isavuconazole both bound tightly to recombinant A. fumigatus CYP51 isoenzymes A and B (AfCYP51A and AfCYP51B) isolated in Escherichia coli membranes.	isavuconazole	17-30	sterol 14-demethylase	Saccharomyces cerevisiae S288C	78-83
31310805-8	2019	However, complementation studies in Saccharomyces cerevisiae using strains containing AfCYP51A and AfCYP51B showed isavuconazole to be equally as effective at inhibiting CYP51 activity as voriconazole.	isavuconazole	115-128	sterol 14-demethylase	Saccharomyces cerevisiae S288C	88-93
31310805-9	2019	These in vitro studies suggest that isavuconazole is an effective alternative to voriconazole as an antifungal agent against the target CYP51 in A. fumigatus.	isavuconazole	36-49	sterol 14-demethylase	Saccharomyces cerevisiae S288C	136-141
31024507-14	2019	Fusarium keratoplasticum showed high MIC values (8->32 mug mL-1) for itraconazole, voriconazole, posaconazole, and isavuconazole.	isavuconazole	118-131	2'-5' oligoadenylate synthetase 1B	Mus musculus	62-66
29558838-0	2019	Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.	isavuconazole	0-13	fms related receptor tyrosine kinase 3	Homo sapiens	28-32
29558838-6	2019	Isavuconazole, a moderate CYP3A4 inhibitor, was successfully initiated and maintained, while midostaurin therapy was also administered.	isavuconazole	0-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	26-32
29022838-6	2017	Expert opinion: Currently studies demonstrating the pharmacogenomic influences on itraconazole, posaconazole and isavuconazole are minimal and limited to their inhibitory effects on CYP3A4 in expressors of CYP3A5 variants.	isavuconazole	113-126	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	206-212
30295407-1	2019	INTRODUCTION: Isavuconazole, a triazole antifungal, is an inhibitor of cytochrome P450 3A4, which also metabolizes tacrolimus and sirolimus.	isavuconazole	14-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-90
30477963-5	2018	In addition, isavuconazole may inhibit CYP3A4.	isavuconazole	13-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-45
28355467-4	2017	Isavuconazole, the newest triazole agent, offers the advantages of once-daily dosing, a wider spectrum of antifungal activity than voriconazole, predictable pharmacokinetics and fewer CYP enzyme-mediated drug interactions.	isavuconazole	0-13	peptidylprolyl isomerase G	Homo sapiens	184-187
26482310-7	2016	Relative increases of azole MICs (from 4- to 32-fold) were observed for fluconazole, voriconazole, and isavuconazole when at least two mutations were present in the same ERG11 allele.	isavuconazole	103-116	sterol 14-demethylase	Saccharomyces cerevisiae S288C	170-175
27273149-0	2017	Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.	isavuconazole	27-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	67-82
27273149-4	2017	Thus, isavuconazole is a mild inducer of CYP2B6 but does not appear to affect CYP1A2-, CYP2C8-, or CYP2D6-mediated metabolism.	isavuconazole	6-19	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	41-47
27273461-0	2017	Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.	isavuconazole	72-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36
27273461-1	2017	This report describes the phase 1 trials that evaluated the metabolism of the novel triazole antifungal isavuconazole by cytochrome P450 3A4 (CYP3A4) and isavuconazole"s effects on CYP3A4-mediated metabolism in healthy adults.	isavuconazole	104-117	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-140
27273461-1	2017	This report describes the phase 1 trials that evaluated the metabolism of the novel triazole antifungal isavuconazole by cytochrome P450 3A4 (CYP3A4) and isavuconazole"s effects on CYP3A4-mediated metabolism in healthy adults.	isavuconazole	104-117	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-148
27273461-1	2017	This report describes the phase 1 trials that evaluated the metabolism of the novel triazole antifungal isavuconazole by cytochrome P450 3A4 (CYP3A4) and isavuconazole"s effects on CYP3A4-mediated metabolism in healthy adults.	isavuconazole	104-117	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	181-187
27273461-1	2017	This report describes the phase 1 trials that evaluated the metabolism of the novel triazole antifungal isavuconazole by cytochrome P450 3A4 (CYP3A4) and isavuconazole"s effects on CYP3A4-mediated metabolism in healthy adults.	isavuconazole	154-167	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	181-187
27273461-2	2017	Coadministration of oral isavuconazole (100 mg once daily) with oral rifampin (600 mg once daily; CYP3A4 inducer) decreased isavuconazole area under the concentration-time curve (AUCtau ) during a dosing interval by 90% and maximum concentration (Cmax ) by 75%.	isavuconazole	25-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
27273461-2	2017	Coadministration of oral isavuconazole (100 mg once daily) with oral rifampin (600 mg once daily; CYP3A4 inducer) decreased isavuconazole area under the concentration-time curve (AUCtau ) during a dosing interval by 90% and maximum concentration (Cmax ) by 75%.	isavuconazole	124-137	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
27273461-3	2017	Conversely, coadministration of isavuconazole (200 mg single dose) with oral ketoconazole (200 mg twice daily; CYP3A4 inhibitor) increased isavuconazole AUC from time 0 to infinity (AUC0-  ) and Cmax by 422% and 9%, respectively.	isavuconazole	32-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	111-117
27273461-3	2017	Conversely, coadministration of isavuconazole (200 mg single dose) with oral ketoconazole (200 mg twice daily; CYP3A4 inhibitor) increased isavuconazole AUC from time 0 to infinity (AUC0-  ) and Cmax by 422% and 9%, respectively.	isavuconazole	139-152	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	111-117
27273461-4	2017	Isavuconazole was coadministered (200 mg 3 times daily for 2 days, then 200 mg once daily) with single doses of oral midazolam (3 mg; CYP3A4 substrate) or ethinyl estradiol/norethindrone (35 mug/1 mg; CYP3A4 substrate).	isavuconazole	0-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	134-140
27273461-4	2017	Isavuconazole was coadministered (200 mg 3 times daily for 2 days, then 200 mg once daily) with single doses of oral midazolam (3 mg; CYP3A4 substrate) or ethinyl estradiol/norethindrone (35 mug/1 mg; CYP3A4 substrate).	isavuconazole	0-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	201-207
27273461-7	2017	These results indicate that isavuconazole is a sensitive substrate and moderate inhibitor of CYP3A4.	isavuconazole	28-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
27821435-5	2017	When NMEs were considered as victim drugs, 21 NMEs had at least one positive clinical DDI, with three NMEs shown to be sensitive substrates of CYP3A (AUC ratio >= 5 when coadministered with strong inhibitors): cobimetinib, isavuconazole (the active metabolite of prodrug isavuconazonium sulfate), and ivabradine.	isavuconazole	226-239	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-148
27821435-5	2017	When NMEs were considered as victim drugs, 21 NMEs had at least one positive clinical DDI, with three NMEs shown to be sensitive substrates of CYP3A (AUC ratio >= 5 when coadministered with strong inhibitors): cobimetinib, isavuconazole (the active metabolite of prodrug isavuconazonium sulfate), and ivabradine.	isavuconazole	274-297	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-148
27273004-6	2017	These findings indicate that isavuconazole is a weak inhibitor of P-gp, as well as OCT1, OCT2, MATE1, or a combination thereof but not of BCRP, OATP1B1, OAT1, or OAT3.	isavuconazole	29-42	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
27273004-6	2017	These findings indicate that isavuconazole is a weak inhibitor of P-gp, as well as OCT1, OCT2, MATE1, or a combination thereof but not of BCRP, OATP1B1, OAT1, or OAT3.	isavuconazole	29-42	solute carrier family 22 member 1	Homo sapiens	83-87
27273004-6	2017	These findings indicate that isavuconazole is a weak inhibitor of P-gp, as well as OCT1, OCT2, MATE1, or a combination thereof but not of BCRP, OATP1B1, OAT1, or OAT3.	isavuconazole	29-42	solute carrier family 22 member 2	Homo sapiens	89-93
27273004-6	2017	These findings indicate that isavuconazole is a weak inhibitor of P-gp, as well as OCT1, OCT2, MATE1, or a combination thereof but not of BCRP, OATP1B1, OAT1, or OAT3.	isavuconazole	29-42	solute carrier family 47 member 1	Homo sapiens	95-100
27001813-4	2016	Fifty percent inhibitory concentrations (IC50s) for P-gp and BCRP were both 2 muM for itraconazole, 5 and 12 muM for hydroxyitraconazole, 3 and 6 muM for posaconazole, and 3 and 11 muM for isavuconazole, respectively.	isavuconazole	189-202	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
27001813-4	2016	Fifty percent inhibitory concentrations (IC50s) for P-gp and BCRP were both 2 muM for itraconazole, 5 and 12 muM for hydroxyitraconazole, 3 and 6 muM for posaconazole, and 3 and 11 muM for isavuconazole, respectively.	isavuconazole	189-202	BCR pseudogene 1	Homo sapiens	61-65
26482310-10	2016	Resistance mechanisms in yeasts involving ABC transporters and ERG11 decreased the activity of isavuconazole, while MDR1 had limited effect.	isavuconazole	95-108	sterol 14-demethylase	Saccharomyces cerevisiae S288C	63-68